Galway, Ireland, February 17, 2010 (ots/PRNewswire) – Cappella (http://www.cappella-med.com/), Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced the addition of Mr. Eamonn Hobbs to the Board of Directors ( http://www.cappella-med.eu/index.php?option= com_content&view=article&id=181:board-of-directors&catid=4) . According to Mr. Wolfgang Oster, MD, PhD, Chairman of the Board and Managing Partner [...]
Tag Archive > Md Phd
Boehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer
Ingelheim, Germany (ots/PRNewswire) – Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], for its efficacy [...]
Pitavastatin is Non-Inferior to Atorvastatin and Simvastatin and Demonstrates Sustained Efficacy and Tolerability Over 52 Weeks
Barcelona, Spain (ots/PRNewswire) – – Pitavastatin Represents Long-Term Treatment Option for Patients With Primary Hypercholesterolaemia or Combined Dyslipidaemia New phase III data presented at the European Society of Cardiology congress (ESC) demonstrated that pitavastatin is non-inferior to atorvastatin and simvastatin at usual therapeutic doses in patients with primary hypercholesterolemia or combined dyslipidemia, as measured by [...]
Helix BioPharma gibt die Berufung von Kazimierz Roszkowski-Sliz, MD, PhD, in den Unternehmensvorstand bekannt
Aurora, Ontario (ots/PRNewswire) – Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) gab heute die Berufung von Kazimierz Roszkowski-Sliz, MD, PhD, in den Vorstand des Unternehmens bekannt. Professor Roszkowski-Sliz löst Professor Slawomir Majewski ab, der aus dem Vorstand zurückgetreten ist, um die beratende Rolle des europäischen medizinischen Direktors für Helix zu übernehmen. Professor Roszkowski-Sliz [...]
Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 (Tovok(TM)) as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations
Ingelheim, Germany (ots/PRNewswire) – – Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC) INGELHEIM, Germany, August 3 /PRNewswire/ — Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung [...]
CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
Maidenhead, England, November 21 (ots/PRNewswire) – – Not for UK Journalists The European Committee for Medicinal Products for Human Use (CHMP) today announced its positive recommendation for the approval of Enbrel(R) (etanercept) as a treatment for children aged 8 years and over and adolescents with severe plaque psoriasis. If approved by the European Commission, following [...]
